• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在肝素诱导的血小板减少症情况下旋磨术期间使用奥曲肽。

Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia.

作者信息

Hale L P, Smith K, Braden G A, Owen J

机构信息

Section on Hematology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA.

出版信息

Cathet Cardiovasc Diagn. 1998 Nov;45(3):318-22. doi: 10.1002/(sici)1097-0304(199811)45:3<318::aid-ccd23>3.0.co;2-2.

DOI:10.1002/(sici)1097-0304(199811)45:3<318::aid-ccd23>3.0.co;2-2
PMID:9829897
Abstract

Heparin is considered necessary during percutaneous coronary interventions; however, heparin is contraindicated in patients with heparin-induced thrombocytopenia and/or heparin antibodies. We describe the successful use of the heparinoid Orgaran (danaparoid sodium) in addition to abciximab (ReoPro) in a patient with heparin antibodies who required rotational atherectomy.

摘要

在经皮冠状动脉介入治疗期间，肝素被认为是必需的；然而，肝素在肝素诱导的血小板减少症和/或存在肝素抗体的患者中是禁忌的。我们描述了在一名需要旋磨术且存在肝素抗体的患者中，除了使用阿昔单抗（ReoPro）之外，成功使用类肝素药物Orgaran（达那肝素钠）的情况。

相似文献

1
Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia.在肝素诱导的血小板减少症情况下旋磨术期间使用奥曲肽。
Cathet Cardiovasc Diagn. 1998 Nov;45(3):318-22. doi: 10.1002/(sici)1097-0304(199811)45:3<318::aid-ccd23>3.0.co;2-2.
2
Combined use of Orgaran and Reopro during coronary angioplasty in patients unable to receive heparin.在无法接受肝素治疗的患者进行冠状动脉血管成形术期间联合使用奥加兰和瑞替普酶。
Catheter Cardiovasc Interv. 1999 Mar;46(3):352-5. doi: 10.1002/(SICI)1522-726X(199903)46:3<352::AID-CCD21>3.0.CO;2-7.
3
Options to heparin anticoagulation for cardiac interventions.心脏介入治疗中肝素抗凝的替代方案。
Catheter Cardiovasc Interv. 1999 Mar;46(3):356. doi: 10.1002/(SICI)1522-726X(199903)46:3<356::AID-CCD22>3.0.CO;2-0.
4
Heparinoid anticoagulation and topical fibrin sealant in heparin-induced thrombocytopenia.类肝素抗凝与局部纤维蛋白封闭剂治疗肝素诱导的血小板减少症
Ann Thorac Surg. 1997 Dec;64(6):1815-7. doi: 10.1016/s0003-4975(97)01065-5.
5
Treatment of heparin-induced thrombocytopenia.肝素诱导的血小板减少症的治疗。
J Thorac Cardiovasc Surg. 1997 Sep;114(3):517-8. doi: 10.1016/S0022-5223(97)70219-8.
6
Heparin-induced thrombocytopenia type II: perioperative management using danaparoid in a coronary artery bypass patient with renal failure.II型肝素诱导的血小板减少症：在一名患有肾衰竭的冠状动脉搭桥手术患者中使用达那肝素进行围手术期管理。
Thorac Cardiovasc Surg. 1997 Dec;45(6):318-20. doi: 10.1055/s-2007-1013759.
7
[Thrombocytopenia due to heparin therapy. Use of danaparoid (Orgaran), 13 monocentric cases under authorization of temporary prescription (ATU)].[肝素治疗所致血小板减少症。达那肝素（Orgaran）的应用，13例单中心临时处方授权（ATU）病例]
Therapie. 1997 Nov-Dec;52(6):591-7.
8
[Danaparoid (orgaran) for continuous venovenous hemodiafiltration in a patient with heparin-induced thrombocytopenia].[达那肝素（奥加兰）用于肝素诱导的血小板减少症患者的持续静脉-静脉血液透析滤过治疗]
Ann Fr Anesth Reanim. 1998;17(1):82-3. doi: 10.1016/s0750-7658(97)80191-8.
9
Use of danaparoid during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia.肝素诱导的血小板减少症患者在体外循环期间使用达那肝素。
J Cardiothorac Vasc Anesth. 2000 Dec;14(6):707-9. doi: 10.1053/jcan.2000.18531.
10
Heparin-induced thrombocytopenia type II: successful use of Orgaran (ORG 10172) in intensive care patients.II型肝素诱导的血小板减少症：在重症监护患者中成功使用奥加诺（ORG 10172）
Intensive Care Med. 1995 Jun;21(6):542-3. doi: 10.1007/BF01706210.

引用本文的文献

1
Management of heparin-induced thrombocytopenia: systematic reviews and meta-analyses.肝素诱导的血小板减少症的管理：系统评价与荟萃分析
Blood Adv. 2020 Oct 27;4(20):5184-5193. doi: 10.1182/bloodadvances.2020002963.
2
American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.美国血液学会 2018 年静脉血栓栓塞症管理指南：肝素诱导的血小板减少症。
Blood Adv. 2018 Nov 27;2(22):3360-3392. doi: 10.1182/bloodadvances.2018024489.
3
Anticoagulation for acute coronary syndromes and percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
Curr Cardiol Rep. 2001 Sep;3(5):362-70. doi: 10.1007/s11886-001-0052-7.